Supplemental Filing to be effective 2/1/2026.

Filed Date: 11/9/26.

Accession Number: 20261109–5188.

Comment Date: 5 p.m. ET 11/23/26.

Any person desiring to protest in any of the above proceedings must file in accordance with Rule 211 of the Commission's Regulations (18 CFR 385.211) on or before 5:00 p.m. Eastern Time on the specified comment date.

The filings are accessible in the Commission's eLibrary system (*https://elibrary.ferc.gov/idmws/search/fercgensearch.asp*) by querying the docket number.

eFiling is encouraged. More detailed information relating to filing requirements, interventions, protests, service, and qualifying facilities filings can be found at: *http://www.ferc.gov/docs-filing/efiling/filing-req.pdf.* For other information, call (866) 208–3676 (toll free). For TTY, call (202) 502–8659.

For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, contact the Office of Public Participation at (202) 502–6595 or *OPP@ferc.gov.*

Dated: November 10, 2026.

Carlos D. Clay,

Deputy Secretary.

[FR Doc. 2026–23284 Filed 11–13–26; 8:45 am]

BILLING CODE 6717–01–P

ENVIRONMENTAL PROTECTION AGENCY

[EPA–HQ–OPPT–2018–0430; FRL–137087–01–OCSPP]

1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[γ]-2-benzopyran (HHCB); Risk Evaluation Under the Toxic Substances Control Act (TSCA); Notice of Data Availability and Request for Comment

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: The Environmental Protection Agency (EPA or Agency) is announcing the availability of data and supporting materials related to the draft risk evaluation under the Toxic Substances Control Act (TSCA) for 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[γ]-2-benzopyran (HHCB) (CASRN 1222–05–5). These materials are intended to inform the public and interested parties about the information considered by the Agency in the draft risk evaluation. During the public comment period for the draft risk evaluation of HHCB (April 14, 2026, to June 15, 2026), EPA became aware of an inadvertent administrative issue in its Health and Environmental Research Online (HERO) system that made 24 industry-submitted studies considered in *Draft Risk Evaluation for 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[γ]-2-benzopyran (HHCB)* unavailable to the public. On October 14, 2026, this issue was resolved and the studies were made available to the public in HERO. The Agency invites interested persons to review the newly available materials in the context of the draft risk evaluation and submit comments within a 30-day comment period.

DATES: Comments must be received on or before December 16, 2026.

ADDRESSES: The docket for this action, identified by docket identification (ID) number EPA–HQ–OPPT–2018–0430, is available online at *https://www.regulations.gov.* Additional information about dockets generally, along with instructions for visiting the docket in person, is available at *https://www.epa.gov/dockets.*

FOR FURTHER INFORMATION CONTACT:

For technical information: Jeffery Putt, Existing Chemical Risk Management Division (7404M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460–0001; telephone number: (202) 564–3703; email address: *HHCB.TSCA@epa.gov.*

For general information: The TSCA-Hotline, ABVI-Goodwill, 422 South Clinton Ave., Rochester, NY 14620; telephone number: (202) 554–1404; email address: *TSCA-Hotline@epa.gov.*

SUPPLEMENTARY INFORMATION:

I. Executive Summary

A. Does this action apply to me?

This action is directed to the public in general and may be of particular interest to those involved in the manufacture (defined under TSCA section 3(9) to include import), processing, distribution, use, and disposal of HHCB, related industry trade organizations, non-governmental organizations with an interest in human and environmental health, State and local governments, Tribal Nations, and/or those interested in the assessment of risks involving chemical substances and mixtures regulated under TSCA. As such, the Agency has not attempted to describe all the specific entities that this action might apply to. If you need help determining applicability, consult the technical contact listed under **FOR FURTHER INFORMATION CONTACT**.

B. What is the Agency's authority for taking this action?

The Agency is conducting the draft risk evaluation under TSCA section 6, 15 U.S.C. 2605, which requires that EPA conduct risk evaluations on chemical substances and identifies the minimum components EPA must include in the risk evaluations. Each risk evaluation must be conducted consistent with the best available science, be based on the weight of the scientific evidence, and consider reasonably available information, and not consider costs or non-risk factors. 15 U.S.C. 2625(h), (i), and (k). See also the implementing procedural regulations at 40 CFR part 702 and for more information about the TSCA risk evaluation process for existing chemicals, go to *https://www.epa.gov/assessing-and-managing-chemicals-under-tsca.*

C. What action is the Agency taking?

EPA is announcing the availability and providing a 30-day public comment period on supporting materials for the draft risk evaluation under TSCA for HHCB. These materials are intended to inform the public and interested parties about the information considered by the Agency in the draft risk evaluation. During the public comment period for the draft risk evaluation of HHCB (April 14, 2026, to June 15, 2026), EPA became aware of an administrative issue in its HERO system that made 24 industry-submitted studies considered in *Draft Risk Evaluation for 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[γ]-2-benzopyran (HHCB)* unavailable to the public. On October 14, 2026, this issue was resolved and the studies were made available to the public in HERO (*https://hero.epa.gov*). A list of these 24 studies can be found in the memo titled *HHCB Data Availability Memorandum,* which is located in docket EPA–HQ–OPPT–2018–0430. The Agency invites interested persons to review the newly available materials in the context of the draft risk evaluation and submit comments.

D. What should I consider as I prepare my comments?

1. Submitting CBI

Do not submit CBI to EPA through *https://www.regulations.gov* or email. If you wish to include CBI in your comment, please follow the applicable instructions at *https://www.epa.gov/dockets/commenting-epa-dockets#rules* and clearly mark the information that you claim to be CBI. Information so marked will not be disclosed except in

accordance with procedures set forth in 40 CFR parts 2 and 703, as applicable.

2. Tips for Preparing Your Comments

When preparing and submitting your comments, see the commenting tips at *https://www.epa.gov/dockets/commenting-epa-dockets.*

II. Background

A. What is HHCB?

HHCB is primarily used as a synthetic musk compound found widely in fragrances. HHCB is utilized in household products such as detergents, cleaners, and air fresheners. HHCB is also a key ingredient in non-TSCA uses including perfumes, cosmetics, and personal care products due to its long-lasting scent properties. Workers may be exposed to HHCB through dust, mist, or vapor when making or using these products. Consumers may be exposed to HHCB through dust, mist, or vapor during intended product use (*e.g.,* cleaning a counter, placing an air freshener in a bathroom or small room, or doing laundry). Environmental releases occur primarily when fragrance products are disposed of down the drain, leading to HHCB entering wastewater and, after treatment, being discharged in effluent from Publicly Owned Treatment Works (POTWs). HHCB may also enter wastewater through transfers of manufacturing wastes to POTWs.

B. Risk Evaluation of HHCB

In December 2019, EPA announced its designation of HHCB (Docket ID: EPA–HQ–OPPT–2018–0430) as a high-priority substance for risk evaluation under TSCA. In April 2020, EPA published and sought public comment on the draft scope of the HHCB risk evaluation (85 FR 19941, April 9, 2020) (FRL–10007–11–OCSPP) and, after considering public comments, issued the final scope in August 2020 (85 FR 55281, September 4, 2020) (FRL–10013–90–OCSPP). In April 2026, EPA released the *Draft Risk Evaluation for 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[γ]-2-benzopyran (HHCB)* for public comment and external peer review by the Science Advisory Committee on Chemicals (SACC) (85 FR 19941, April 06, 2026) (FRL–13304–01–OCSPP).

III. Request for Comment

EPA seeks feedback on the newly available supporting materials in the context of the draft risk evaluation under TSCA for HHCB. Specifically, EPA seeks feedback 24 studies considered in the *Draft Human Health and Environmental Hazard Assessment for 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[γ]-2-benzopyran (HHCB)* that were inadvertently not accessible due to an administrative issue with the HERO database during the public comment period for the draft risk evaluation of HHCB (April 14, 2026, to June 15, 2026). A copy of the memo which includes a list of the newly available 24 studies can be found in docket EPA–HQ–OPPT–2018–0430. EPA encourages all potentially interested parties, including individuals, governmental and non-governmental organizations, non-profit organizations, academic institutions, research institutions, and private sector entities to provide comment during the 30-day public comment period.

IV. Next Steps

EPA will consider comments received on this notice of data availability submitted to the docket while finalizing the HHCB risk evaluation. EPA will announce the availability of the final risk evaluation for HHCB in the coming months. Under TSCA section 6, EPA must use the final risk evaluation as a basis to determine, based on the weight of scientific evidence, whether or not the chemical presents an unreasonable risk to health or the environment under the chemical's conditions of use. This includes risks to subpopulations who may be at greater risks than the general population, such as children and workers. TSCA prohibits EPA from considering non-risk factors (*e.g.,* costs/benefits) during risk evaluation.

If at the end of the risk evaluation process, EPA determines that a chemical presents an unreasonable risk to health or the environment under the conditions of use, the chemical must move to risk management action under TSCA section 6(a). EPA is required to implement, via regulation, regulatory restrictions on the manufacture (including import), processing, distribution, use, or disposal of the chemical to eliminate the identified unreasonable risk. Like the prioritization and risk evaluation processes, there is an opportunity for public comment on any proposed risk management actions.

For more information about the TSCA risk evaluation process for existing chemicals, go to *https://www.epa.gov/assessing-and-managing-chemicals-under-tsca.*

Authority: 15 U.S.C. 2601 *et seq.*

Dated: November 12, 2026.

Douglas M. Troutman,

Assistant Administrator, Office of Chemical Safety and Pollution Prevention.

[FR Doc. 2026–23263 Filed 11–13–26; 8:45 am]

BILLING CODE 6560–50–P

FEDERAL COMMUNICATIONS COMMISSION

[OMB 3060–0546, OMB 3060–1326; FR ID 377154]

Information Collections Being Reviewed by the Federal Communications Commission Under Delegated Authority

AGENCY: Federal Communications Commission.

ACTION: Notice; request for comments.

SUMMARY: As part of its continuing effort to reduce paperwork burdens, and as required by the Paperwork Reduction Act (PRA) of 1995, the Federal Communications Commission (Commission) invites the general public and other Federal agencies to take this opportunity to comment on the following information collection. Comments are requested concerning: whether the collection of information is necessary for the proper performance of the functions of the Commission, including whether the information shall have practical utility; the accuracy of the Commission's burden estimate; ways to enhance the quality, utility, and clarity of the information collected; ways to minimize the burden of the collection of information on the respondents, including the use of automated collection techniques or other forms of information technology; and ways to further reduce the information collection burden on small business concerns with fewer than 25 employees.

DATES: Written PRA comments should be submitted on or before January 15, 2027. If you anticipate that you will be submitting comments but find it difficult to do so within the period of time allowed by this notice, you should advise the contact listed below as soon as possible.

ADDRESSES: Direct all PRA comments to Cathy Williams, FCC, via email to *PRA@fcc.gov* and to *Cathy.Williams@fcc.gov*.

FOR FURTHER INFORMATION CONTACT: For additional information or copies of the information collection, contact Cathy Williams at (202) 418–2918.

SUPPLEMENTARY INFORMATION: The FCC may not conduct or sponsor a collection of information unless it displays a